No. of patients | 155 | 36 | 119 | |
No. of glands | 216 | 97 | 119 | |
Mean age (yr) | 60 (range, 14–88) | 59 | 60 | |
Female | 108 (67%) | 25 (69%) | 83 (70%) | |
4D-CT characteristics | | | | |
Mean size of abnormal glands (mm) | 10.9 (5.9) | 8.8 (4.0) | 11.7 (6.4) | .002 |
Median size of abnormal glands (mm) (IQR) | 10 (7–13) | 8 (6–11) | 11 (7–13) | |
No. <10 mm (%) | 79 (37%) | 39 (64%) | 40 (34%) | |
No. <7 mm (%) | 30 (14%) | 19 (31%) | 11 (9%) | |
No. >13 mm (%) | 39 (18%) | 6 (10%) | 33 (28%) | |
Prospectively detected lesions | | | | |
1 | 100 | 10b | 90 | <.001 |
≥2 | 46 | 20 | 26 | |
None | 9 | 6 | 3 | |
Biochemical markers | | | | |
Serum calcium level (mg/dL) | 11.0 (0.7) | 10.8 (0.4) | 11.1 (0.7) | .07 |
Serum parathyroid hormone level (pg/mL) | 117 (69) | 92 (44) | 122 (73) | .02 |
WIN | 1279 (744) | 1005 (501) | 1357 (783) | .01 |
MGD scores | | | | |
Composite MGD score | 2.6 (1.6) | 4.1 (1.4) | 2.2 (1.4) | <.001 |
4D-CT MGD score | 1.6 (1.4) | 2.9 (1.1) | 1.2 (1.2) | <.001 |
4D-CT sensitivity based on original radiology reports | | | | |
Detection of lesions | 167 (77%) | 53 (55%) | 114 (95%) | |
Detection of all lesions in individual patients | 126 (81%) | 12 (33%) | 114 (95%) | |